• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of pediatric hematology/oncology: Official journal of the American Society of Pediatric Hematology/Oncology >Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Retrospective Cohort Study
【24h】

Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Retrospective Cohort Study

机译：2009年1月至2009年12月，用修饰的柏林 - 法兰克福 - MueNster /香港急性淋巴细胞/香港急性淋巴细胞/香港急性淋巴细胞/香港急性淋巴细胞/香港急性淋巴细胞白血病（BFM95 / HKALL97）议定书进行急性淋巴细胞白血病的生存结果：回顾性队列研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This retrospective cohort study is primarily aimed to evaluate the outcome of children ages 0 to 18 years old, with acute lymphoblastic leukemia and treated with a modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95-HKALL97) protocol at University of Santo Tomas Hospital from January 2005 to December 2009. Seventy-eight patients were included. Majority were between 1 and 10 years old (87.2%), male (61.5%), with normal nutritional status, and classified as upper socioeconomic class (65.3%), mainly from National Capital Region (24.3%). Eighty percent had mild anemia and a white cell count < 50,000/mm(3). No patient had an initial platelet count < 20,000/mm(3). More than 90% were standard risk, with FAB L1 morphology and pre-B immunophenotype. Five-year overall survival (OS) and event-free survival (EFS) rates were 86.94% and 86.2%, respectively. Among the 69 patients in the efficacy subset analysis, the 5-year OS and EFS rates were 98.36% and 86.80%, respectively. Relapse rate was 14.5%. Only FAB morphology and risk classification were correlated with relapse. Most common complications were febrile neutropenia, sepsis, and oral mucositis during induction phase. No deaths occurred due to treatment complications. In conclusion, using higher doses of methotrexate during consolidation phase improved the 5-year OS and EFS rates of our patients, without an increase in complications or deaths. Other contributing factors include improved adherence to treatment and risk-based treatment classification.
机译：该回顾性队列研究主要旨在评估0至18岁的儿童的结果，急性淋巴细胞白血病，并在Santo大学用改良的柏林 - 法兰克福 - Muenster /香港急性淋巴细胞白血病（BFM95-HKALL97）协议治疗2005年1月至2009年12月的Tomas医院。包括七十八名患者。大多数人在1到10岁之间（87.2％），男性（61.5％），营养状况正常，并被归类为上部社会经济阶层（65.3％），主要来自国家资本区域（24.3％）。百分之八十贫血和白细胞计数<50,000 / mm（3）。患者没有初始血小板数<20,000 / mm（3）。超过90％是标准风险，具有Fab L1形态和预b前免疫蛋白型。为期五年的整体生存（OS）和无需生存（EFS）率分别为86.94％和86.2％。在69例疗效子集分析中，5年的OS和EFS率分别为98.36％和86.80％。复发率为14.5％。只有Fab形态和风险分类与复发相关。在诱导阶段期间，大多数常见的并发症是发热中性粒细胞病，脓毒症和口腔粘膜炎。由于治疗并发症，没有发生死亡。总之，在合并阶段期间使用较高剂量的甲氨蝶呤改善了我们患者的5年的OS和EFS率，而不会增加并发症或死亡。其他贡献因素包括改善遵守治疗和基于风险的治疗分类。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号